- Home
- ORGO vs GAIN Comparison
ORGO vs GAIN Comparison
Compare ORGO & GAIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGO
- GAIN
- Stock Information
- Founded
- ORGO 1985
- GAIN 2005
- Country
- ORGO United States
- GAIN United States
- Employees
- ORGO N/A
- GAIN N/A
- Industry
- ORGO Biotechnology: Pharmaceutical Preparations
- GAIN Finance: Consumer Services
- Sector
- ORGO Health Care
- GAIN Finance
- Exchange
- ORGO Nasdaq
- GAIN Nasdaq
- Market Cap
- ORGO 533.9M
- GAIN 497.3M
- IPO Year
- ORGO N/A
- GAIN 2005
- Fundamental
- Price
- ORGO $3.11
- GAIN $14.21
- Analyst Decision
- ORGO Buy
- GAIN Hold
- Analyst Count
- ORGO 2
- GAIN 1
- Target Price
- ORGO $5.50
- GAIN $13.50
- AVG Volume (30 Days)
- ORGO 2.1M
- GAIN 110.6K
- Earning Date
- ORGO 05-08-2025
- GAIN 05-13-2025
- Dividend Yield
- ORGO N/A
- GAIN 10.65%
- EPS Growth
- ORGO N/A
- GAIN N/A
- EPS
- ORGO N/A
- GAIN 1.92
- Revenue
- ORGO $458,760,000.00
- GAIN $89,176,000.00
- Revenue This Year
- ORGO $3.31
- GAIN $6.75
- Revenue Next Year
- ORGO $12.50
- GAIN $12.51
- P/E Ratio
- ORGO N/A
- GAIN $7.35
- Revenue Growth
- ORGO 5.35
- GAIN 6.78
- 52 Week Low
- ORGO $2.17
- GAIN $11.42
- 52 Week High
- ORGO $6.71
- GAIN $14.85
- Technical
- Relative Strength Index (RSI)
- ORGO 31.37
- GAIN 65.24
- Support Level
- ORGO $2.88
- GAIN $13.67
- Resistance Level
- ORGO $5.55
- GAIN $13.98
- Average True Range (ATR)
- ORGO 0.39
- GAIN 0.26
- MACD
- ORGO -0.23
- GAIN 0.04
- Stochastic Oscillator
- ORGO 7.68
- GAIN 88.46
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About GAIN Gladstone Investment Corporation Business Development Company
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to (i) achieve and grow current income by investing in debt securities of established businesses. (ii) provide our stockholders with long-term capital appreciation in the value of our assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.